NEW YORK (GenomeWeb News) – Cellular analysis technologies company Cyntellect has raised $3 million in financing in an equity, debt, and warrant options sale, according to a filing with the US Securities and Exchange Commission.
Cyntellect’s technologies include in situ, microplate-based cytometry instruments for use in cell-based diagnostics and therapeutics.
The company did not disclose in the SEC filing the investors involved in the purchase or how it plans to use the funds. However, it did say that the investment was not related to any merger or acquisition.
The San Diego-based company brought in around $15 million in Series D venture financing in July 2007.